We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+18.47%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.6B
AUM Growth
+$886M
Cap. Flow
+$257M
Cap. Flow %
4.58%
Top 10 Hldgs %
40.08%
Holding
154
New
29
Increased
38
Reduced
31
Closed
27

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$93.3M
2
BMY icon
Bristol-Myers Squibb
BMY
+$82.6M
3
SHPG
Shire pic
SHPG
+$76.4M
4
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$50.3M
5
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$49.2M

Top Sells

Rank Stock Value
1
ONXX
ONYX PHARMACEUTICALS INC
ONXX
+$149M
2
INCY icon
Incyte
INCY
+$33.4M
3
MAKO
MAKO SURGICAL CORP COM
MAKO
+$26.7M
4
PFE icon
Pfizer
PFE
+$25.6M
5
AGN
Allergan plc
AGN
+$23.7M

Sector Composition

Rank Sector Weight
1 Healthcare 85.38%
2 Miscellaneous 12.69%
3 Financials 1.77%
4 Technology 0.15%
5 Utilities 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGN
26
DELISTED
Allergan plc
AGN
$68.4M 1.22%
475,100
-178,100
-27% -$23.7M
IPXL
27
DELISTED
Impax Laboratories, Inc.
IPXL
$67.3M 1.2%
3,285,700
+25,100
+0.8% +$518K
MOH icon
28
Molina Healthcare
MOH
$11.2B
$65.3M 1.17%
1,834,000
+169,000
+10% +$6.24M
CBST
29
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$57.5M 1.03%
904,200
+814,200
+905% +$49.2M
JNJ icon
30
Johnson & Johnson
JNJ
$642B
$56.6M 1.01%
653,000
+452,000
+225% +$40.5M
WCRX
31
DELISTED
WARNER CHILCOTT PLC ORD SHS CL A (IRL)
WCRX
$56.2M 1%
2,449,100
-304,000
-11% -$6.43M
EXAS
32
DELISTED
Exact Sciences
EXAS
$55.2M 0.99%
4,680,300
-21,600
-0.5% -$277K
EXEL icon
33
Exelixis
EXEL
$13.9B
$50.9M 0.91%
+8,744,000
New +$45.3M
SPY icon
34
State Street SPDR S&P 500 ETF Trust
SPY
$803B
$50.4M 0.9%
+300,000
New +$50.3M
ITMN
35
DELISTED
INTERMUNE INC
ITMN
$44.4M 0.79%
2,887,600
+2,651,600
+1,124% +$37.2M
CFN
36
DELISTED
CAREFUSION CORPORATION
CFN
$44.4M 0.79%
1,203,300
+1,048,400
+677% +$39.1M
AFFX
37
DELISTED
Affymetrix Inc
AFFX
$41.2M 0.73%
6,648,000
+272,600
+4% +$1.41M
NXTM
38
DELISTED
NxStage Medical Inc.
NXTM
$41M 0.73%
3,114,500
-106,600
-3% -$1.4M
HNT
39
DELISTED
HEALTH NET INC
HNT
$40.2M 0.72%
1,269,600
+619,600
+95% +$19.6M
ALGN icon
40
Align Technology
ALGN
$10.9B
$36.8M 0.66%
766,000
-58,000
-7% -$2.53M
CI icon
41
Cigna
CI
$74.2B
$33.7M 0.6%
438,000
+11,000
+3% +$859K
SPY icon
42
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$803B
$33.6M 0.6%
200,000
-100,000
-33% -$16.8M
LAB icon
43
Standard BioTools
LAB
$271M
$31.1M 0.55%
1,416,608
+153,900
+12% +$3.02M
ARRY
44
DELISTED
Array Biopharma Inc
ARRY
$30.1M 0.54%
4,831,600
-33,400
-0.7% -$198K
OSUR icon
45
OraSure Technologies
OSUR
$224M
$29.2M 0.52%
4,860,100
+99,800
+2% +$500K
AGN
46
DELISTED
Allergan Inc
AGN
$26.9M 0.48%
297,000
-5,000
-2% -$449K
CNC icon
47
Centene
CNC
$34.3B
$26.8M 0.48%
1,673,200
– –
VRTX icon
48
Vertex Pharmaceuticals
VRTX
$132B
$25.6M 0.46%
338,000
+115,000
+52% +$9.15M
ALXN
49
DELISTED
Alexion Pharmaceuticals
ALXN
$25.1M 0.45%
215,900
+23,000
+12% +$2.52M
XNPT
50
DELISTED
XENOPORT, INC.
XNPT
$24M 0.43%
4,222,600
+181,800
+4% +$949K
1
2
3 4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q3 2013 Portfolio in Review

As of Q3 2013, OrbiMed held 154 positions worth $5.6B, up 19% from $4.72B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

OrbiMed deployed $257M of net new capital in Q3 2013, opening 29 new positions and adding to 38 existing holdings. Its largest new stake was Shire pic: 690,900 shares worth $82.8M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 82% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Incyte, an estimated $33.4M trimmed.

  • OrbiMed's largest Q3 2013 buy was Shire pic: 690,900 shares worth $82.8M.
  • OrbiMed added most to Merck in Q3 2013, an estimated $93.3M increase.
  • OrbiMed's biggest Q3 2013 reduction was Incyte, cutting an estimated $33.4M.
  • OrbiMed fully exited ONYX PHARMACEUTICALS INC in Q3 2013, selling an estimated $149M.
  • OrbiMed's ten largest holdings make up 40% of its $5.6B portfolio in Q3 2013.
  • OrbiMed opened 29 new positions and closed 27 in Q3 2013.
  • OrbiMed's portfolio value rose 19% quarter-over-quarter to $5.6B.

Based on OrbiMed's 13F filing for Q3 2013, filed 14 Nov 2013.